{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:45:01Z","timestamp":1773175501448,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV drug resistance (HIVDR) continues to threaten the effectiveness of worldwide antiretroviral therapy (ART). Emergence and transmission of HIVDR are driven by several interconnected factors. Though much has been done to uncover factors influencing HIVDR, overall interconnectedness between these factors remains unclear and African policy makers encounter difficulties setting priorities combating HIVDR. By viewing HIVDR as a complex adaptive system, through the eyes of multi-disciplinary HIVDR experts, we aimed to make a first attempt to linking different influencing factors and gaining a deeper understanding of the complexity of the system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We designed a detailed systems map of factors influencing HIVDR based on semi-structured interviews with 15 international HIVDR experts from or with experience in sub-Saharan Africa, from different disciplinary backgrounds and affiliated with different types of institutions. The resulting detailed system map was conceptualized into three main HIVDR feedback loops and further strengthened with literature evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Factors influencing HIVDR in sub-Saharan Africa and their interactions were sorted in five categories: biology, individual, social context, healthcare system and \u2018overarching\u2019. We identified three causal loops cross-cutting these layers, which relate to three interconnected subsystems of mechanisms influencing HIVDR. The \u2018adherence motivation\u2019 subsystem concerns the interplay of factors influencing people living with HIV to alternate between adherence and non-adherence. The \u2018healthcare burden\u2019 subsystem is a reinforcing loop leading to an increase in HIVDR at local population level. The \u2018ART overreliance\u2019 subsystem is a balancing feedback loop leading to complacency among program managers when there is overreliance on ART with a perceived low risk to drug resistance. The three subsystems are interconnected at different levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Interconnectedness of the three subsystems underlines the need to act on the entire system of factors surrounding HIVDR in sub-Saharan Africa in order to target interventions and to prevent unwanted effects on other parts of the system. The three theories that emerged while studying HIVDR as a complex adaptive system form a starting point for further qualitative and quantitative investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-022-12738-4","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T05:06:57Z","timestamp":1646629617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Exploring the mechanisms behind HIV drug resistance in sub-Saharan Africa: conceptual mapping of a complex adaptive system based on multi-disciplinary expert insights"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-9144","authenticated-orcid":false,"given":"Anneleen","family":"Kiekens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Dierckx de Casterl\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampietro","family":"Pellizzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idda H.","family":"Mosha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausta","family":"Mosha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias F.","family":"Rinke de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael Z.","family":"Sangeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Surian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico","family":"Vandaele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbet","family":"Vranken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Japhet","family":"Killewo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Mieke","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"12738_CR1","unstructured":"UN Joint Programme on HIV\/AIDS (UNAIDS). 90\u201390\u201390 An ambitious treatment target to help end the AIDS epidemic. In: United Nations [Internet]. 2014 [cited 19 Sep 2019]. Available: https:\/\/www.unaids.org\/en\/resources\/documents\/2017\/90-90-90."},{"key":"12738_CR2","unstructured":"World Health Organization (WHO). HIV Drug Resistance Report 2019. Geneva, Switserland; 2019."},{"key":"12738_CR3","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/infdis\/jix089","volume":"215","author":"AN Phillips","year":"2017","unstructured":"Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, et al. Impact of HIV drug resistance on HIV\/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa. J Infect Dis. 2017;215:1362\u20135. https:\/\/doi.org\/10.1093\/infdis\/jix089.","journal-title":"J Infect Dis"},{"key":"12738_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S2666-5247(20)30058-6","volume":"5247","author":"RL Hamers","year":"2020","unstructured":"Hamers RL, Inzaule SC. Pan-resistant HIV-1: what\u2019s next? Lancet Microbe. 2020;5247:11\u20132. https:\/\/doi.org\/10.1016\/S2666-5247(20)30058-6.","journal-title":"Lancet Microbe"},{"key":"12738_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2666-5247(20)30006-9","volume":"5247","author":"MC Puertas","year":"2020","unstructured":"Puertas MC, Ploumidis G, Ploumidis M, Fumero E, Clotet B, Walworth CM, et al. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. Lancet Microbe. 2020;5247:1\u20136. https:\/\/doi.org\/10.1016\/S2666-5247(20)30006-9.","journal-title":"Lancet Microbe"},{"key":"12738_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2217\/fvl-2017-0019","volume":"12","author":"S Rusconi","year":"2017","unstructured":"Rusconi S. The impact of adherence to HIV\/AIDS antiretroviral therapy on the development of drug resistance. Future Virol. 2017;12:239\u201341. https:\/\/doi.org\/10.2217\/fvl-2017-0019.","journal-title":"Future Virol"},{"key":"12738_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002183","volume":"13","author":"Z Shubber","year":"2016","unstructured":"Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016;13:1\u201314. https:\/\/doi.org\/10.1371\/journal.pmed.1002183.","journal-title":"PLoS Med"},{"key":"12738_CR8","doi-asserted-by":"publisher","first-page":"S812","DOI":"10.1093\/infdis\/jix403","volume":"216","author":"T Minior","year":"2017","unstructured":"Minior T, Douglas M, Edgil D, Srivastava M, Crowley J, Firth J, et al. The Critical Role of Supply Chains in Preventing Human Immunodeficiency Virus Drug Resistance in Low-And Middle-Income Settings. J Infect Dis. 2017;216:S812\u20135. https:\/\/doi.org\/10.1093\/infdis\/jix403.","journal-title":"J Infect Dis"},{"key":"12738_CR9","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s10461-013-0683-x","volume":"18","author":"K Rough","year":"2014","unstructured":"Rough K, Dietrich J, Essien T, Gray G, Katz IT. Whoonga and the Abuse and Diversion of Antiretrovirals in Soweto. South Africa AIDS Behav. 2014;18:1378\u201380. https:\/\/doi.org\/10.1007\/s10461-013-0683-x.","journal-title":"South Africa AIDS Behav"},{"key":"12738_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S1473-3099(12)70294-3","volume":"13","author":"D Grelotti","year":"2013","unstructured":"Grelotti D, Closson EF, Matthew M. Pretreatment antiretroviral exposure from recreational use. Lancet. 2013;13:10\u20132. https:\/\/doi.org\/10.1016\/S1473-3099(12)70294-3.","journal-title":"Lancet"},{"key":"12738_CR11","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1007\/s10461-020-02821-5","volume":"24","author":"C Kuo","year":"2021","unstructured":"Kuo C, Giovenco D, Deatley T, Hoare J, Underhill K, Atujuna M, et al. Recreational use of HIV antiretroviral medication and implications for HIV pre-exposure prophylaxis and treatment. AIDS Behav. 2021;24:2650\u20135. https:\/\/doi.org\/10.1007\/s10461-020-02821-5.","journal-title":"AIDS Behav"},{"key":"12738_CR12","doi-asserted-by":"publisher","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-selassie H, Tanuri A, Forero LA, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries\u202f: a systematic review and meta-regression analysis. Lancet Infect Dis. 2020;18:346\u201355. https:\/\/doi.org\/10.1016\/S1473-3099(17)30702-8.","DOI":"10.1016\/S1473-3099(17)30702-8"},{"key":"12738_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/bmj.323.7313.625","volume":"323","author":"PE Plsek","year":"2001","unstructured":"Plsek PE, Greenhalgh T. Complexity science: The challenge of complexity in health care. [Article 1 in series of 4]. BMJ. 2001;323:625\u20138. https:\/\/doi.org\/10.1136\/bmj.323.7313.625.","journal-title":"BMJ"},{"key":"12738_CR14","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1016\/S0140-6736(17)31267-9","volume":"390","author":"H Rutter","year":"2017","unstructured":"Rutter H, Savona N, Glonti K, Bibby J, Cummins S, Finegood DT, et al. The need for a complex systems model of evidence for public health. Lancet. 2017;390:2602\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(17)31267-9.","journal-title":"Lancet"},{"key":"12738_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1126\/science.aal1950","volume":"356","author":"R DeFries","year":"2017","unstructured":"DeFries R, Nagendra H. Ecosystem management as a wicked problem. Science. 2017;356:265\u201370.","journal-title":"Science"},{"key":"12738_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3945\/an.114.006650","volume":"5","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xue H, Esposito L, Joyner M, Bar-yam Y. Applications of Complex Systems Science in Obesity and Noncommunicable Chronic Disease Research. Am Soc Nutr. 2018;5:574\u20137. https:\/\/doi.org\/10.3945\/an.114.006650.","journal-title":"Am Soc Nutr"},{"key":"12738_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/bmj.323.7315.746","volume":"323","author":"PE Plsek","year":"2001","unstructured":"Plsek PE, Wilson T. Complexity science: Complexity, leadership, and management in healthcare organisations. Br Med J. 2001;323:746\u20139. https:\/\/doi.org\/10.1136\/bmj.323.7315.746.","journal-title":"Br Med J"},{"key":"12738_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/jep.12856","volume":"24","author":"E Rusoja","year":"2018","unstructured":"Rusoja E, Haynie D, Sievers J, Mustafee N, Nelson F, Reynolds M, et al. Thinking about complexity in health: A systematic review of the key systems thinking and complexity ideas in health. J Eval Clin Pract. 2018;24:600\u20136. https:\/\/doi.org\/10.1111\/jep.12856.","journal-title":"J Eval Clin Pract"},{"key":"12738_CR19","doi-asserted-by":"publisher","unstructured":"Decouttere C, Vandaele N, De Boeck K, Banzimana S. A Systems-Based Framework for Immunisation System Design: Six Loops, Three Flows, Two Paradigms. Fac Econ Business, KU Leuven. 2020. doi:https:\/\/doi.org\/10.1101\/2021.07.19.21260775.","DOI":"10.1101\/2021.07.19.21260775"},{"issue":"1","key":"12738_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-13-997","volume":"13","author":"F Yaya","year":"2013","unstructured":"Yaya F, Bocoum S, Kouanda, Kouyat\u00e9 B, Hounton S, Adam T. Exploring the effects of task shifting for HIV through a systems thinking lens: The case of Burkina Faso. BMC Public Health. 2013;13(1):1\u201310. https:\/\/doi.org\/10.1186\/1471-2458-13-997.","journal-title":"BMC Public Health"},{"issue":"1","key":"12738_CR21","first-page":"78","volume":"91","author":"D Meadows","year":"1997","unstructured":"Meadows D. Places to Intervene in a System. Whole Earth. 1997;91(1):78\u201384.","journal-title":"Whole Earth"},{"key":"12738_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/sres.2145","volume":"30","author":"NC Nguyen","year":"2013","unstructured":"Nguyen NC, Bosch OJH. A Systems Thinking Approach to identify Leverage Points for Sustainability: A Case Study in the Cat Ba Biosphere Reserve. Vietnam Nam Syst Res Behav Sci. 2013;30:104\u201315. https:\/\/doi.org\/10.1002\/sres.2145.","journal-title":"Vietnam Nam Syst Res Behav Sci"},{"key":"12738_CR23","doi-asserted-by":"publisher","unstructured":"Mcglashan J, Johnstone M, Creighton D, De HK, Allender S. Quantifying a Systems Map\u202f: Network Analysis of a Childhood Obesity Causal Loop Diagram. PLoS ONE. 2016;11:1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0165459.","DOI":"10.1371\/journal.pone.0165459"},{"key":"12738_CR24","doi-asserted-by":"publisher","unstructured":"Braithwaite J, Churruca K, Long JC, Ellis LA, Herkes J. When complexity science meets implementation science\u202f: a theoretical and empirical analysis of systems change. BMC Med. 2018;16:1\u201314. https:\/\/doi.org\/10.1186\/s12916-018-1057-z.","DOI":"10.1186\/s12916-018-1057-z"},{"issue":"3","key":"12738_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijnurstu.2011.09.012","volume":"49","author":"B Dierckx de Casterl\u00e9","year":"2012","unstructured":"Dierckx de Casterl\u00e9 B, Gastmans C, Bryon E, Denier Y. QUAGOL: A guide for qualitative data analysis. Int J Nurs Stud. 2012;49(3):360\u201371. https:\/\/doi.org\/10.1016\/j.ijnurstu.2011.09.012.","journal-title":"Int J Nurs Stud"},{"key":"12738_CR26","unstructured":"Mohr J, Mohr R. KUMU Inc. 2011. Available: https:\/\/kumu.io"},{"key":"12738_CR27","unstructured":"Kiekens A, Dierckx de Casterl\u00e9 B, Pellizzer G, Mosha I, Mosha F, Rinke de Wit TF, et al. Interactive systems maps of factors influencing HIVDR in sub-Saharan Africa. Available: https:\/\/annemie.kumu.io\/identifying-mechanisms-behind-hiv-drug-resistance-in-sub-saharan-africa-a-systems-approach?token=meUKVHYzmT1jrNse."},{"key":"12738_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0210408","volume":"14","author":"I Eshun-Wilson","year":"2019","unstructured":"Eshun-Wilson I, Rohwer A, Hendricks L, Oliver S, Garner P. Being HIV positive and staying on antiretroviral therapy in Africa: A qualitative systematic review and theoretical model. PLoS ONE. 2019;14:1\u201330. https:\/\/doi.org\/10.1371\/journal.pone.0210408.","journal-title":"PLoS ONE"},{"key":"12738_CR29","unstructured":"World Health Organization. Density of physicians. In: Geneva, Switserland [Internet]. 2019 [cited 2 Apr 2020]. Available: https:\/\/www.who.int\/gho\/health_workforce\/physicians_density\/en\/."},{"issue":"1","key":"12738_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-13-308","volume":"13","author":"J Fokam","year":"2013","unstructured":"Fokam J, Billong SC, Bissek ACZK, Kembou E, Milenge P, Abessouguie I, et al. Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008 \u2013 2010\u202f: lessons and challenges for low-resource settings. BMC Public Health. 2013;13(1):1\u201310. https:\/\/doi.org\/10.1186\/1471-2458-13-308.","journal-title":"BMC Public Health"},{"key":"12738_CR31","unstructured":"Kuriakose S, George J, Dee N, Stoll P, Agan BK, Dewar RL, et al. High Level Resistance to Dolutegravir (DTG) after Emergence of T97A Mutation. CROI. 2018. Available: http:\/\/www.natap.org\/2018\/CROI\/croi_140.htm."},{"key":"12738_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/nejmc1908155","volume":"381","author":"N L\u00fcbke","year":"2019","unstructured":"L\u00fcbke N, Jensen B, H\u00fcttig F, Feldt T, Walker A, Kaiser R, et al. Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R. N Engl J Med. 2019;381:885\u20137. https:\/\/doi.org\/10.1056\/nejmc1908155.","journal-title":"N Engl J Med"},{"key":"12738_CR33","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1093\/jac\/dkaa355","volume":"75","author":"E Ndashimye","year":"2020","unstructured":"Ndashimye E, Avino M, Olabode AS, Poon AFY, Gibson RM, Li Y, et al. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. J Antimicrob Chemother. 2020;75:3525\u201333. https:\/\/doi.org\/10.1093\/jac\/dkaa355.","journal-title":"J Antimicrob Chemother"},{"key":"12738_CR34","unstructured":"Siedner MJ, Moorhouse MA, Hill A, Oliveira T De, Lessells R, Simmons B, et al. Pre-Treatment HIV Drug Resistance and Virologic Outcomes in the ADVANCE Trial. CROI. 2020. Available: https:\/\/www.croiconference.org\/abstract\/pretreatment-hiv-drug-resistance-and-48-week-virologic-outcomes-in-the-advance-trial\/."},{"key":"12738_CR35","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","volume":"5","author":"RL Hamers","year":"2018","unstructured":"Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV. 2018;5:e588\u201396. https:\/\/doi.org\/10.1016\/S2352-3018(18)30173-5.","journal-title":"Lancet HIV"},{"key":"12738_CR36","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/S1473-3099(18)30710-2","volume":"19","author":"SC Inzaule","year":"2019","unstructured":"Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. Lancet Infect Dis. 2019;19:e246\u201352. https:\/\/doi.org\/10.1016\/S1473-3099(18)30710-2.","journal-title":"Lancet Infect Dis"},{"key":"12738_CR37","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.2105\/AJPH.2011.300149","volume":"101","author":"AVD Roux","year":"2011","unstructured":"Roux AVD. Complex Systems Thinking and Current Impasses in Health Disparities Research. Am J Public Health. 2011;101:1627\u201335. https:\/\/doi.org\/10.2105\/AJPH.2011.300149.","journal-title":"Am J Public Health"},{"key":"12738_CR38","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3390\/pathogens10121535","volume":"10","author":"A Kiekens","year":"2021","unstructured":"Kiekens A, Mosha IH, Zlati\u0107 L, Bwire GM, Mangara A, de Casterl\u00e9 BD, et al. Factors Associated with HIV Drug Resistance in Dar es Salaam, Tanzania: Analysis of a Complex Adaptive System. Pathogens. 2021;10:1535. https:\/\/doi.org\/10.3390\/pathogens10121535.","journal-title":"Pathogens"},{"key":"12738_CR39","doi-asserted-by":"crossref","unstructured":"Chapman K. Complexity and creative capacity. 1st ed. New \u00ddork: Routledge; 2016.","DOI":"10.4324\/9781315680767"},{"key":"12738_CR40","unstructured":"Belgian Law regarding research on human subjects of 7\/5\/2004. [cited 8 Feb 2021]. Available: http:\/\/www.ejustice.just.fgov.be\/cgi_loi\/change_lg.pl?language=nl&la=N&table_name=wet&cn=2004050732."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-12738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-12738-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-12738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T05:13:41Z","timestamp":1646630021000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-12738-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["12738"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-12738-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-764469\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"7 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project is not within the scope of the Belgian Law regarding research on human subjects of 7\/5\/2004 [\n                      \n                      ]. This study did not involve patients and the interview did not contain personal questions, but rather involved questions about expert opinions on an international scientific problem, therefore, ethics approval was not required. Before the interviews began, all experts were informed about study\u2019s aim and methods and provided informed verbal consent for participation in the study. Participation was voluntary and the experts were free to terminate the interview at any time. Data was collected between October 2018 and February 2020. Face to face interviews were done in Italy and South Africa. We obtained a statement of a local ethical committee confirming that ethical approval in Italy was not necessary. We also refer to the Italian law of 5 June 2019 \u201cgarante per la protezione dei dati personali\u201d. None of the four experts interviewed during a conference in South Africa, had the South African nationality. Ethical approval was not needed for this research as the South African Health Act of 2003 covers only research done on South African citizens. The interviewees were not study subjects but rather provided their professional opinion about a complex public health problem. Moreover, both the researcher who conducted the interviews and the principal investigator followed a South African good clinical practice course.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AV declares consultancy fee from Gilead.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"455"}}